Main menu button

Carlsquare Equity Research interview with Biosergen

Equity Research
23 Sep 2024

Carlsquare Equity Research interview with Biosergen
Niklas Elmhammer
Niklas Elmhammer LinkedIn
Senior Equity Analyst
+46 70 898 39 59

Similar News

Equity research Pila Pharma H1 2026: From rat detour to clinical heat
28 Aug 2026
Equity research Pila Pharma H1 2026: From rat detour to clinical heat
Equity Research Pila Pharma
Equity research Zinzino Q2 2026: Strong profitability trend
26 Aug 2026
Equity research Zinzino Q2 2026: Strong profitability trend
Equity Research Zinzino
Equity research WPTG, Q2 2026: AI pivot accelerates growth and margins
26 Aug 2026
Equity research WPTG, Q2 2026: AI pivot accelerates growth and margins
Equity Research White Pearl Technology Group
Equity research Zinzino Q2 2026: First impression - ZZ tops estimates, maintains outlook
25 Aug 2026
Equity research Zinzino Q2 2026: First impression - ZZ tops estimates, maintains outlook
Equity Research Zinzino
Equity research Viva Wine Group Q2 2026: Margin relief in a soft market
21 Aug 2026
Equity research Viva Wine Group Q2 2026: Margin relief in a soft market
Equity Research Viva Wine Group